News | November 10, 2023
GSK registers 5% revenue growth in Q2 FY24
General Medicine grows 5% and Vaccines 10% led by Shingrix
General Medicine grows 5% and Vaccines 10% led by Shingrix
This product will be manufactured at Lupin’s Pithampur facility in India
The companies plan to start a pivotal Phase 3 trial in the coming months
RHTC will address a long-standing healthcare access issue for all the local population
Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients
New Molecular biology lab launched, AIIA increased its work scope in form of MoUs
The vaccine further advances Pfizer’s vaccine portfolio and builds on more than 20 years of expertise and knowledge in the prevention of meningococcal disease
Profit after tax (before exceptional items) up 23% to Rs 215 crores
Glenmark's Zita portfolio of medicines have been benefiting around 1.75 million Type 2 diabetic patients annually
Over 34 lakh children and 6 lakh pregnant women were administered vaccine doses during the first 2 rounds of IMI 5.0 campaign across the country
Subscribe To Our Newsletter & Stay Updated
